Nuclear receptor ligand-binding domains three-dimensional structures, molecular interactions and pharmacological implications

被引:419
作者
Bourguet, W [1 ]
Germain, P [1 ]
Gronemeyer, H [1 ]
机构
[1] ULP, CNRS, INSERM, IGBMC, F-67404 Illkirch Graffenstaden, De Strasbour, France
关键词
D O I
10.1016/S0165-6147(00)01548-0
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Nuclear receptors are members of a large family of ligand-inducible transcription factors that regulate gene programs underlying a plethora of (patho)physiological phenomena. The recent determination of the crystal structures of nuclear receptor ligand-binding domains has provided an extremely detailed insight into the intra- and intermolecular mechanisms that constitute the initial events of receptor activation and signal transduction. Here, a comprehensive mechanistic view of agonist and antagonist action will be presented. Furthermore, the novel class of partial agonists-antagonists will be described and the multiple challenges and novel perspectives for nuclear-receptor-based drug design will be discussed.
引用
收藏
页码:381 / 388
页数:8
相关论文
共 60 条
[1]
Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1α with multiple steroid receptors and identification of an internally deleted ELE1β isoform [J].
Alen, P ;
Claessens, F ;
Schoenmakers, E ;
Swinnen, JV ;
Verhoeven, G ;
Rombauts, W ;
Peeters, B .
MOLECULAR ENDOCRINOLOGY, 1999, 13 (01) :117-128
[2]
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968
[3]
Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists [J].
Barkhem, T ;
Carlsson, B ;
Nilsson, Y ;
Enmark, E ;
Gustafsson, JÅ ;
Nilsson, S .
MOLECULAR PHARMACOLOGY, 1998, 54 (01) :105-112
[4]
ROLE OF THE 2 ACTIVATING DOMAINS OF THE ESTROGEN-RECEPTOR IN THE CELL-TYPE AND PROMOTER-CONTEXT DEPENDENT AGONISTIC ACTIVITY OF THE ANTIESTROGEN 4-HYDROXYTAMOXIFEN [J].
BERRY, M ;
METZGER, D ;
CHAMBON, P .
EMBO JOURNAL, 1990, 9 (09) :2811-2818
[5]
SXR, a novel steroid and xenobiotic-sensing nuclear receptor [J].
Blumberg, B ;
Sabbagh, W ;
Juguilon, H ;
Bolado, J ;
van Meter, CM ;
Ono, ES ;
Evans, RM .
GENES & DEVELOPMENT, 1998, 12 (20) :3195-3205
[6]
Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains [J].
Bourguet, W ;
Vivat, V ;
Wurtz, JM ;
Chambon, P ;
Gronemeyer, H ;
Moras, D .
MOLECULAR CELL, 2000, 5 (02) :289-298
[7]
CRYSTAL-STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA [J].
BOURGUET, W ;
RUFF, M ;
CHAMBON, P ;
GRONEMEYER, H ;
MORAS, D .
NATURE, 1995, 375 (6530) :377-382
[8]
Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[9]
Chang CY, 1999, MOL CELL BIOL, V19, P8226
[10]
RAR-SPECIFIC AGONIST/ANTAGONISTS WHICH DISSOCIATE TRANSACTIVATION AND AP1 TRANSREPRESSION INHIBIT ANCHORAGE-INDEPENDENT CELL-PROLIFERATION [J].
CHEN, JY ;
PENCO, S ;
OSTROWSKI, J ;
BALAGUER, P ;
PONS, M ;
STARRETT, JE ;
RECZEK, P ;
CHAMBON, P ;
GRONEMEYER, H .
EMBO JOURNAL, 1995, 14 (06) :1187-1197